Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5

Bibliography

• Gregory KJ, Conn PJ. Molecular insights into metabotropic glutamate receptor allosteric modulation. Mol Pharmacol 2015;88(1):188-202
   PubMed Web of Science ®Google Scholar
• Dore AS, Okrasa K, Patel JC, et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 2014;511(7511):557-62
   PubMed Web of Science ®Google Scholar
• Nickols HH, Conn PJ. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis 2014;61:55-71
   PubMed Web of Science ®Google Scholar
• Noetzel MJ, Gregory KJ, Vinson PN, et al. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol 2013;83(4):835-47
   PubMed Web of Science ®Google Scholar
• Lindemann L, Porter RH, Scharf SH, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther 2015;353(1):213-33
   PubMed Web of Science ®Google Scholar
• Zhang Y, Rodriguez AL, Conn PJ. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther 2005;315(3):1212-19
   PubMed Web of Science ®Google Scholar
• Fuxe K, Agnati LF, Jacobsen K, et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson’s disease. Neurology 2003;61(11 Suppl 6):S19-23
   PubMedGoogle Scholar
• Vallano A, Fernandez-Duenas V, Garcia-Negredo G, et al. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson’s disease: bridging molecular studies and clinical trials. CNS Neurol Disord Drug Targets 2013;12(8):1128-42
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Bruno V, Ngomba RT, et al. Metabotropic glutamate receptors as drug targets: what’s new? Curr Opin Pharmacol 2015;20:89-94
   PubMed Web of Science ®Google Scholar
• Scharf SH, Jaeschke G, Wettstein JG, Lindemann L. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr Opin Pharmacol 2015;20:124-34
   PubMed Web of Science ®Google Scholar
• Petrov D, Pedros I, de Lemos ML, et al. Mavoglurant as a treatment for Parkinson’s disease. Expert Opin Investig Drugs 2014;23(8):1165-79
   PubMed Web of Science ®Google Scholar
• Zarate CAJr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64
   PubMed Web of Science ®Google Scholar
• Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013;73(12):1133-41
   PubMed Web of Science ®Google Scholar
• Chaki S, Ago Y, Palucha-Paniewiera A, et al. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013;66:40-52
   PubMed Web of Science ®Google Scholar
• Pisani A, Calabresi P, Centonze D, Bernardi G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 1997;120(6):1007-14
   PubMed Web of Science ®Google Scholar
• Homayoun H, Stefani MR, Adams BW, et al. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology 2004;29(7):1259-69
   PubMed Web of Science ®Google Scholar
• Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007;62(7):739-46
   PubMed Web of Science ®Google Scholar
• Rosenbrock H, Kramer G, Hobson S, et al. Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator. Eur J Pharmacol 2010;639(1-3):40-6
   PubMed Web of Science ®Google Scholar
• Petralia RS. Distribution of extrasynaptic NMDA receptors on neurons. ScientificWorldJournal 2012;2012:267120
   PubMed Web of Science ®Google Scholar
• Jin DZ, Guo ML, Xue B, et al. Differential regulation of CaMKIIalpha interactions with mGluR5 and NMDA receptors by Ca(2+) in neurons. J Neurochem 2013;127(5):620-31
   PubMed Web of Science ®Google Scholar
• Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012;338(6103):68-72
   PubMed Web of Science ®Google Scholar
• Thompson SM, Kallarackal AJ, Kvarta MD, et al. An excitatory synapse hypothesis of depression. Trends Neurosci 2015;38(5):279-94
   PubMed Web of Science ®Google Scholar
• Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012;62(1):63-77
   PubMed Web of Science ®Google Scholar
• Li X, Need AB, Baez M, Witkin JM. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006;319(1):254-9
   PubMed Web of Science ®Google Scholar
• Liu CY, Jiang XX, Zhu YH, Wei DN. Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: role of brain-derived neurotrophic factor. Neuroscience 2012;223:219-24
   PubMed Web of Science ®Google Scholar
• Pilc A, Chaki S, Nowak G, Witkin JM. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008;75(5):997-1006
   PubMed Web of Science ®Google Scholar
• Jaeschke G, Kolczewski S, Spooren W, et al. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. J Med Chem 2015;58(3):1358-71
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Tamburri P, Deptula D, et al. The efficacy and safety of basimglurant as adjuntive therapy in major depression; a randomized double-blind, placebo-controlled study. In: European Congress of Neuropsychopharmacology (ECNP). Eur Neuropsychopharmacol 2014;468
   Google Scholar
• Fuxe K, Dahlstrom A, Hoistad M, et al. From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission. Brain Res Rev 2007;55(1):17-54
   PubMed Web of Science ®Google Scholar
• Fuxe K, Ungerstedt U. Localization of 5-hydroxytryptamine uptake in rat brain after intraventricular injection. J Pharm Pharmacol 1967;19(5):335-7
   PubMed Web of Science ®Google Scholar
• Carlsson A, Fuxe K, Ungerstedt U. The effect of imipramine on central 5-hydroxytryptamine neurons. J Pharm Pharmacol 1968;20(2):150-1
   PubMed Web of Science ®Google Scholar
• Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 2010;79(5):267-79
   PubMed Web of Science ®Google Scholar
• Fuxe K, Ogren SO, Agnati L, et al. On the mechanism of action of the antidepressant drugs amitriptyline and nortriptyline. Evidence for 5-hydroxytryptamine receptor blocking activity. Neurosci Lett 1977;6(4):339-43
   PubMed Web of Science ®Google Scholar
• Borroto-Escuela DO, Narvaez M, Marcellino D, et al. Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization. Biochem Biophys Res Commun 2010;393(4):767-72
   PubMed Web of Science ®Google Scholar
• Borroto-Escuela DO, Romero-Fernandez W, Mudo G, et al. Fibroblast growth factor receptor 1- 5-hydroxytryptamine 1A heteroreceptor complexes and their enhancement of hippocampal plasticity. Biol Psychiatry 2012;71(1):84-91
   PubMed Web of Science ®Google Scholar
• Borroto-Escuela DO, Narvaez M, Perez-Alea M, et al. Evidence for the existence of FGFR1-5-HT1A heteroreceptor complexes in the midbrain raphe 5-HT system. Biochem Biophys Res Commun 2015;456(1):489-93
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185(1):1-10
   PubMed Web of Science ®Google Scholar
• Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30(11):563-9
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67(8):793-802
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008;28(6):631-7
   PubMed Web of Science ®Google Scholar
• Mott DD, Doherty JJ, Zhang S, et al. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1998;1(8):659-67
   PubMed Web of Science ®Google Scholar
• Hunkeler W, Kyburz E, Meier M. Imidazodiazepine derivatives for treatment of disorders of the central nervous system. US4863920; 1988
   Google Scholar
• Hintermann S, Vranesic I, Allgeier H, et al. ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorg Med Chem 2007;15(2):903-14
   PubMed Web of Science ®Google Scholar
• van Hooft JA, Giuffrida R, Blatow M, Monyer H. Differential expression of group I metabotropic glutamate receptors in functionally distinct hippocampal interneurons. J Neurosci 2000;20(10):3544-51
   PubMed Web of Science ®Google Scholar
• Zhou FM, Hablitz JJ. Metabotropic glutamate receptor enhancement of spontaneous IPSCs in neocortical interneurons. J Neurophysiol 1997;78(5):2287-95
   PubMed Web of Science ®Google Scholar
• Thomas LS, Jane DE, Harris JR, Croucher MJ. Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro. Neuropharmacology 2000;39(9):1554-66
   PubMed Web of Science ®Google Scholar
• Costa-Mattioli M, Monteggia LM. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci 2013;16(11):1537-43
   PubMed Web of Science ®Google Scholar
• Pozzi L, Pollak Dorocic I, Wang X, et al. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLoS ONE 2014;9(1):e83879
   PubMed Web of Science ®Google Scholar
• Miller OH, Yang L, Wang CC, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife 2014;3:e03581
   PubMed Web of Science ®Google Scholar
• Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475(7354):91-5
   PubMed Web of Science ®Google Scholar
• Monteggia LM, Zarate CJr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 2015;30:139-43
   PubMed Web of Science ®Google Scholar
• Nosyreva E, Szabla K, Autry AE, et al. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci 2013;33(16):6990-7002
   PubMed Web of Science ®Google Scholar
• Ogren SO, Fuxe K, Agnati LF, et al. Reevaluation of the indoleamine hypothesis of depression. Evidence for a reduction of functional activity of central 5-HT systems by antidepressant drugs. J Neural Transm 1979;46(2):85-103
   PubMed Web of Science ®Google Scholar
• Blier P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry 2013;74(Suppl 2):19-24
   PubMed Web of Science ®Google Scholar
• Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:54-63
   PubMed Web of Science ®Google Scholar
• Legutko B, Szewczyk B, Pomierny-Chamiolo L, et al. Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacol Rep 2006;58(3):427-30
   PubMed Web of Science ®Google Scholar
• Dahlstroem A, Fuxe K. Evidence for the Existence of Monoamine-Containing Neurons in the Central Nervous System. I. Demonstration of Monoamines in the Cell Bodies of Brain Stem Neurons. Acta Physiol Scand Suppl 1964;232:231-55
   Google Scholar
• Borroto-Escuela DO, Agnati LF, Bechter K, et al. The role of transmitter diffusion and flow versus extracellular vesicles in volume transmission in the brain neural–glial networks. Phil Trans R Soc B 2015;370(1672
   Google Scholar
• Pollak Dorocic I, Furth D, Xuan Y, et al. A whole-brain atlas of inputs to serotonergic neurons of the dorsal and median raphe nuclei. Neuron 2014;83(3):663-78
   PubMed Web of Science ®Google Scholar
• Sharp T, Boothman L, Raley J, Queree P. Important messages in the ’post’: recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 2007;28(12):629-36
   PubMed Web of Science ®Google Scholar
• Smialowska M, Szewczyk B, Branski P, et al. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 2002;42(8):1016-23
   PubMed Web of Science ®Google Scholar
• Gama L, Wilt SG, Breitwieser GE. Heterodimerization of calcium sensing receptors with metabotropic glutamate receptors in neurons. J Biol Chem 2001;276(42):39053-9
   PubMed Web of Science ®Google Scholar
• Deschwanden A, Karolewicz B, Feyissa AM, et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry 2011;168(7):727-34
   PubMed Web of Science ®Google Scholar
• de la Mora MP, Gallegos-Cari A, Arizmendi-Garcia Y, et al. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis. Prog Neurobiol 2010;90(2):198-216
   PubMed Web of Science ®Google Scholar
• Fuxe K, Celani MF, Martire M, et al. l-Glutamate reduces the affinity of [3H]N-propylnorapomorphine binding sites in striatal membranes. Eur J Pharmacol 1984;100(1):127-30
   PubMed Web of Science ®Google Scholar
• Popoli P, Pezzola A, Torvinen M, et al. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 2001;25(4):505-13
   PubMed Web of Science ®Google Scholar
• Ferre S, Karcz-Kubicha M, Hope BT, et al. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci USA 2002;99(18):11940-5
   PubMed Web of Science ®Google Scholar
• Agnati LF, Ferre S, Lluis C, et al. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 2003;55(3):509-50
   PubMed Web of Science ®Google Scholar
• Chase TN, Bibbiani F, Bara-Jimenez W, et al. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003;61(11 Suppl 6):S107-11
   PubMedGoogle Scholar
• Dell’anno MT, Pallottino S, Fisone G. mGlu5R promotes glutamate AMPA receptor phosphorylation via activation of PKA/DARPP-32 signaling in striatopallidal medium spiny neurons. Neuropharmacology 2013;66:179-86
   PubMed Web of Science ®Google Scholar
• Cabello N, Gandia J, Bertarelli DC, et al. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 2009;109(5):1497-507
   PubMed Web of Science ®Google Scholar
• Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, et al. Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field. Neuropsychopharmacology 2014;39(1):131-55
   PubMed Web of Science ®Google Scholar
• Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin Ther Targets 2015;19(3):377-98
   PubMed Web of Science ®Google Scholar
• Guidolin D, Agnati LF, Marcoli M, et al. G-protein-coupled receptor type A heteromers as an emerging therapeutic target. Expert Opin Ther Targets 2015;19(2):265-83
   PubMed Web of Science ®Google Scholar
• Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, et al. Extrasynaptic neurotransmission in the modulation of brain function. Focus on the striatal neuronal-glial networks. Front Physiol 2012;3:136
   Google Scholar
• Tanganelli S, O’Connor WT, Ferraro L, et al. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience 1994;60(3):649-57
   PubMed Web of Science ®Google Scholar
• Tronci V, Balfour DJ. The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on the stimulation of dopamine release evoked by nicotine in the rat brain. Behav Brain Res 2011;219(2):354-7
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Seneca N, Shin RM, et al. Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. J Neurosci 2009;29(6):1887-96
   PubMed Web of Science ®Google Scholar
• Wydra K, Golembiowska K, Suder A, et al. On the role of adenosine (A)(2)A receptors in cocaine-induced reward: a pharmacological and neurochemical analysis in rats. Psychopharmacology (Berl) 2015;232(2):421-35
   PubMed Web of Science ®Google Scholar
• Schroder H, Wu DF, Seifert A, et al. Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the micro-opioid receptor. Neuropharmacology 2009;56(4):768-78
   PubMed Web of Science ®Google Scholar
• Gravius A, Pietraszek M, Dekundy A, Danysz W. Metabotropic glutamate receptors as therapeutic targets for cognitive disorders. Curr Top Med Chem 2010;10(2):187-206
   PubMed Web of Science ®Google Scholar
• Jacob W, Gravius A, Pietraszek M, et al. The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology 2009;57(2):97-108
   PubMed Web of Science ®Google Scholar
• Lu YM, Jia Z, Janus C, et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 1997;17(13):5196-205
   PubMed Web of Science ®Google Scholar
• Marek GJ. Glutamatergic mechanisms in antidepressant treatments. Eur Neuropsychopharm 2002;12:S170-1
   Web of Science ®Google Scholar
• Fuxe K, Borroto-Escuela DO, Ciruela F, et al. Receptor-receptor interactions in heteroreceptor complexes: a new principle in biology. Focus on their role in learning and memory. Neurosci Discov 2014;2(1
   Google Scholar
• Borroto-Escuela DO, Brito I, Romero-Fernandez W, et al. The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components. Int J Mol Sci 2014;15(5):8570-90
   PubMed Web of Science ®Google Scholar